Electrocore (ECOR)

[investar]

Results on Thursday! whisper is they will beat
Price now 1.55$

nVNS therapy stimulates the vagus nerve, which has been proven to help people suffering from a variety of disorders.

https://www.electrocore.com/product/

The 5 analysts offering 12-month price forecasts for electroCore, Inc. have a median target of 3.50, with a high estimate of 5.00 and a low estimate of 3.00.

[investar]

https://finance.yahoo.com/news/electroc ... 00646.html

Positive topline results in Migraine Prevention!

[investar]

Business Update and some guidance:

https://investor.electrocore.com/news-r ... inancial-2

[investar]

This news is quite important and could lead to a multi-day rally in ECOR shares:

https://www.cms.gov/files/document/2020 ... sories.pdf

p 48 to 50

https://finance.yahoo.com/news/electroc ... 00019.html

Would be nice to see a record volume day tomorrow after one or two upgrades and mentions

[investar]

Big news, NHS endorsement:

https://investor.electrocore.com/news-r ... tm-new-nhs

To be included in the MTFM Mandate Policy 2021/22, products must have demonstrated that they:

are effective: as demonstrated through positive NICE guidance (MTG or DG);
are cost-saving in-year: NICE modelling demonstrates a net savings in the first 12 months of implementing the technology;
are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years;
deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England;
The policy can be viewed online at the following link: https://www.england.nhs.uk/aac/wp-conte ... n-2021.pdf


Stock now 3$... 5$ coming soon?

[investar]

Good news from Australia:

https://www.benzinga.com/general/biotec ... -headaches


maybe the run towards 5$ started today.
high volume but closes around intraday lows so it may take a little longer

[investar]

Distirbution deal for headache relief device in Western Europe

And more deals to be expected:

https://scr.zacks.com/news/news-details ... fault.aspx

We anticipate additional deals to be announced in the coming months. Some of the regions that we think are likely to be high on the priority list for electroCore include Western Europe, Middle East and Asia. Revenues from each of the abovementioned agreements should be recognized in 2021. These arrangements are particularly attractive to electroCore given the low capital requirements and minimum purchase requirements.

Corporate Milestones

electroCore has multiple approved indications and is currently pursuing additional ones with active studies in respiratory symptoms in COVID patients, stroke, post-traumatic conditions, traumatic brain injury and others which are at varying stages of advancement. Below we list recent milestones and anticipated future events.

➢ Complete enrollment for SAVIOR-1 – 1Q:21

➢ Clinical publications for PTSD, PTH & TBI – 4Q:20/1Q:21

➢ Premium II data readout – December 2020

➢ Grant of HCPCS code – January 2021

➢ EU stroke data – 1Q:21/2Q:21

➢ Distribution partner announcements outside US – Ongoing



Anticipated Achievements and Milestones (1)

Summary of Investment Thesis

➢ Effective, non-invasive, and non-pharmaceutical method to treat migraines

➢ Portable, simple and rapid solution for preventing and treating headaches

➢ Indicated for both migraines and cluster headaches

➢ Existing and expanding relationships with VA hospitals

➢ Recharge/refill business model

➢ Supply chain simplicity: direct to customer shipping

➢ gammaCore can be prescribed through telemedicine

➢ NHS relationship in UK may provide foundation for further global expansion

◦ Continental Europe

◦ Asia

➢ Multiple distributor agreements with additional agreements expected

◦ Eastern Europe

◦ Canada

◦ Australia

➢ Opportunity for COVID-related sales following EUA award

➢ Extended indications

◦ Stroke

◦ Trauma injury related headaches

◦ PTSD

◦ Mild traumatic brain injury

◦ Inflammation